Adamis Pharmaceuticals Corp (ADMP)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David J. Marguglio
Employees:
20
11455 EL CAMINO REAL, SUITE 310, SAN DIEGO, CA 92130
(858) 997-2400

Adamis Pharmaceuticals Corporation develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Data derived from most recent annual or quarterly report
Market Cap 29.927 Million Shares Outstanding148.89 Million Avg 30-day Volume 693.409 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.11
Price to Revenue20.1134 Debt to Equity0.0 EBITDA-32.432 Million
Price to Book Value10.463 Operating Margin-1938.5422999999998 Enterprise Value27.479 Million
Current Ratio1.137 EPS Growth0.522 Quick Ratio0.448
1 Yr BETA 0.564 52-week High/Low 0.85 / 0.12 Profit Margin-2156.811
Operating Cash Flow Growth14.9799 Altman Z-Score-41.7684 Free Cash Flow to Firm -16.487 Million
View SEC Filings from ADMP instead.

View recent insider trading info

Funds Holding ADMP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADMP

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-04:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-10-04:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-23:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-21:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-12:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-08-17:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-01:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-06:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.02: Unregistered Sales of Equity Securities
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BIRNDORF HOWARD C

    • Director
    58,824 2022-11-14 1

    CARLO DENNIS J PHD

    • FORMER PRESIDENT & CEO
    692,459 2022-05-25 2

    REED VICKIE S

    • Director
    50,000 2022-05-24 2

    MARGUGLIO DAVID J. SVP AND CHIEF BUSINESS OFFICER

    • Officer
    • Director
    239,790 2022-03-18 2

    MOSS RONALD B. CHIEF MEDICAL OFFICER

    • Officer
    201,911 2022-03-18 1

    BENEDICTO DAVID C. CHIEF FINANCIAL OFFICER

    • Officer
    39,875 2022-03-18 1

    DESAI MEERA J.

    • Director
    0 2021-10-01 0

    HOPKINS ROBERT O CHIEF FINANCIAL OFFICER

    277,067 2021-02-21 0

    DANIELS KAREN K. VP OF OPERATIONS

    • Officer
    149,242 2020-12-31 0

    BLUNT ROSHAWN A.

    • Director
    0 2019-08-26 0

    WILLIAMS RICHARD C

    239,918 2019-05-24 0

    ROTHERMEL ROBERT B

    133,500 2019-05-24 0

    DENBY WILLIAM C

    108,750 2019-05-24 0

    GLOVER EDDIE WABERN CEO OF US COMPOUNDING, INC.

    741,668 2018-12-31 0

    MOLL THOMAS VP OF RESEARCH

    • Officer
    0 2018-02-21 0

    RAHMAN AHMED SHAYAN FAZLUR

    ESES HOLDINGS (FZE)

    • 10% Owner
    1,635,312 2015-02-13 0

    NOVA TINA SUSAN

    • Director
    0 2013-10-16 0

    COHEN KENNETH M

    • Director
    0 2013-10-16 0

    JOHNSON CRAIG A

    • Director
    0 2013-10-16 0

    ADAMS JOHN Q

    • Director
    0 2009-04-01 0

    ALOI RICHARD L

    • Director
    3,593,039 2009-04-01 0

    GREGORY JOHN M

    SJ STRATEGIC INVESTMENTS LLC

    GREGORY JOAN P

    GREGORY JAMES M

    PALMER SUSAN

    • 10% Owner
    • MEMBERMEMBERMEMBER
    0 2008-12-16 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BIRNDORF HOWARD C - Director

    2022-11-16 16:41:21 -0500 2022-11-14 D 58,824 d 0 direct

    BIRNDORF HOWARD C - Director

    2022-11-16 16:41:21 -0500 2022-11-14 A 58,824 a 58,824 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 22:15:03 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 21:45:03 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 21:15:03 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 20:45:03 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 20:15:04 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 19:45:04 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 19:15:03 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 18:45:03 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 18:15:04 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 17:45:03 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 17:15:03 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 16:45:04 UTC -0.9249 4.7449 2000000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 16:15:04 UTC -0.9249 4.7449 1700000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 15:45:03 UTC -0.9249 4.7449 1700000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 15:15:03 UTC -0.9249 4.7449 1700000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 14:45:04 UTC -0.9249 4.7449 1700000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 14:15:03 UTC -0.9249 4.7449 1700000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 13:45:03 UTC -1.2127 5.0327 1700000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 13:15:03 UTC -1.2127 5.0327 1700000
    ADAMIS PHARMACEUTICALS CORP ADMP 2022-12-01 12:45:03 UTC -1.2127 5.0327 1700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ADMP -15300.0 shares, $-3037.05 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments